Heart failure and kidney function study
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart failure with reduced pumping function for at least 3 months.
- An echo test within the last 2 years shows your heart pumps out 40% or less blood with each beat.
- You are in New York Heart Association class II or III, meaning you have some symptoms with activity but not at rest.
- Your kidney function (eGFR) has been below 30 for at least one test in the past year and is below 45 at screening.
- You are on stable, optimized heart failure medications for at least 4 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This trial tests whether it is safe and effective to increase heart failure medications (like ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT-2 inhibitors) without frequent kidney monitoring. It is for people with heart failure and reduced ejection fraction who are not yet on full doses of these medicines.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
This study tests an investigational medication called elecoglipron to see if it can improve heart and blood vessel outcomes in people with heart failure with preserved or mildly reduced ejection fraction. If you join, you will receive either the study drug or a placebo, and your heart health will be monitored over time.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This early-phase trial tests a treatment that aims to improve the “natriuretic peptide” hormone system in people with HFpEF (heart failure with preserved pumping strength). It may help reduce symptoms and improve heart and fluid pressure behavior, especially in certain related conditions like kidney disease.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.